Researchers show that glycoRNAs, uncovered by the lab of Nobel Laureate, Carolyn Bertozzi, can be used to fight cancer.

The number of chromosomal alterations observed in AML [2,3] (more than 200 translocations, in addition to several point mutations) is enormous and makes it impossible to screen each one of them as ...

Laboratory analyses showed that the patient who developed AML had significant chromosomal abnormalities and mutations in the RUNX1 and PTPN11 genes typically associated with the development of the ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

genes near known chromosomal breakpoints associated with leukemia and genes with unknown but possibly related functions.

In 2021, research led by Ryan Flynn, MD, PhD, and his mentor, Nobel laureate Carolyn Bertozzi, PhD, opened a new chapter in biology, characterizing a new kind of player on the cell surface: glycoRNAs.

Invivoscribe, a global leader in precision diagnostics, is pleased to announce the successful listings of the LeukoStrat CDx FLT3 Mutation ... diagnosed with acute myeloid leukemia (AML).

AML is an aggressive and rapidly progressing hematologic malignancy. Making timely and accurate detection of actionable mutations such as FLT3 is critical and essential for optimizing patient ...